Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Fengcai Zhu, Xu-Hua Guan, Yu-Hua Li, Jian-Ying Huang, Tao Jiang, Li-Hua Hou, Jingxin Li, Bei-Fang Yang, Ling Wang, Wen-Juan Wang,

The Lancet · 2020 · 1.3K citations · 18 references

DOIFull text

Open access

Concepts

References

18